TARA News and Press, ArTara Therapeutics Inc. From 04/05/24

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate o...

New development pathway significantly expands addressable patient population for IV Choline Chloride IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S. Approximately 80% of PN patients are cho...

TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive /Experienced patients in ongoing NMIBC program TARA-002 demonstrated a complete response rate of 63% at three months in CIS-only patients in ongoing NMIBC program ...

2024-03-23 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you want to strike it rich via stocks to help you retire on a private island, the reality is this: You probably can’t go the buy-and-hold approach that legendary investors like Warren...

Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024 Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS expected in 2H 2024 Cash, cash equivalen...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 44 th ...

2024-01-25 14:20:00 ET Summary With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year’s most highly anticipated IPOs. The company’s lead drug targets a sizable addressable market (NMIBC) where there is an...

New results from six patients with HGTa papillary tumors show five of six patients with HGRFS at Week 12 Data continue to support favorable tolerability of TARA-002 in patients with NMIBC As previously reported, anti-tumor activity observed in all three evaluable patients with C...

2023-11-03 12:29:17 ET Protara Therapeutics ( NASDAQ: TARA ) on Friday filed a prospectus for a mixed securities shelf offering of up to $300M. This prospectus is not an offer to sell these securities. Shares of TARA rose 17.2% . SEC Filing For furth...